{
    "Trade/Device Name(s)": [
        "Elecsys CMV IgG",
        "Elecsys CMV IgG Immunoassay",
        "Elecsys PreciControl CMV IgG"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K220911",
    "Predicate Device Reference 510(k) Number(s)": [
        "K131605"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFZ"
    ],
    "Summary Letter Date": "March 28, 2022",
    "Summary Letter Received Date": "March 29, 2022",
    "Submission Date": "March 28, 2022",
    "Regulation Number(s)": [
        "21 CFR 866.3175"
    ],
    "Regulation Name(s)": [
        "Cytomegalovirus Serological Reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "immunology",
        "serology"
    ],
    "Analyte(s)": [
        "CMV IgG antibodies"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium-heparin plasma",
        "K2-EDTA plasma",
        "K3-EDTA plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "cobas e immunoassay analyzers",
        "cobas e 801 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Two-step sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Electrochemiluminescence detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys CMV IgG immunoassay using electrochemiluminescence on cobas e analyzers for qualitative detection of CMV IgG antibodies",
    "Indications for Use Summary": "In vitro qualitative test for detection of IgG antibodies to CMV in human serum and plasma, aiding serological status determination in individuals including pregnant women; not evaluated for immunocompromised, neonatal screening, point-of-care, or donor screening use",
    "fda_folder": "Microbiology"
}